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Abstract 
Aims: In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial 
fibrillation is 20 mg once daily (od), with 15 mg od recommended in patients with creatinine 
clearance [CrCl] 15–49 mL/min. Non-recommended doses are prescribed in real-world 
practice. This analysis of the XANTUS study assessed outcomes associated with non-
recommended dosing and patient characteristics that may have impacted dose choice. 
Methods and results: Baseline characteristics and 1-year outcomes were compared in 
4464/6784 patients with known CrCl, receiving recommended or non-recommended 
rivaroxaban doses; 3608 (80.8%) patients received recommended doses (mean CHADS2 
score 1.9) and 856 (19.2%) non-recommended doses (mean CHADS2 score 2.5). Incidence 
rate (events/100 patient-years) for the composite of treatment-emergent adjudicated major 
bleeding, stroke/systemic embolism and death was 7.5 (95% confidence interval [CI] 5.7–
9.8) and 4.8 (95% CI 4.1–5.7) with non-recommended and recommended doses, 
respectively (hazard ratio 1.55; 95% CI 1.2–2.1; P = 0.004). Incidence rates for the 
components of the composite were 3.7 and 2.6, 1.4 and 0.9, and 3.5 and 1.9, respectively. 
Adjustment for baseline characteristics showed similar rates of the composite outcome 
(hazard ratio 1.06; 95% CI 0.77–1.45; P = 0.719). Multivariable analysis identified age, 
anaemia, congestive heart failure, diabetes mellitus, CrCl, lower body weight, atrial fibrillation 
type, and vascular disease as predictors of non-recommended dosing. 
Conclusion: Non-recommended rivaroxaban dosing was associated with less favourable 
outcomes, possibly due to baseline characteristics, in addition to renal function, that may 
also affect physicians’ dosing decisions.  
  
Trial registration number: Clinicaltrials.gov: NCT01606995 
Word count: 243/250 words 
 
Key words: anticoagulants, atrial fibrillation, real-world, rivaroxaban, stroke prevention  
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Introduction 
The prevalence of atrial fibrillation (AF) varies from 400–475 per 100,000 population in 
Western Europe to 700–775 per 100,000 in North America and increases with age.1 
Thromboembolic stroke or non-central nervous system (CNS) systemic embolism (SE) is a 
potential complication in patients with AF, which can be reduced with appropriate 
anticoagulation.2 Although vitamin K antagonists (VKAs) are effective in this setting, non-VKA 
oral anticoagulants (NOACs) are the guideline-preferred option.2 NOACs have been shown 
to be at least as effective as warfarin in preventing stroke/non-CNS SE in patients with AF;3-6 
a meta-analysis of all phase III trials assessing the use of NOACs versus warfarin in patients 
with AF showed that NOACs reduced the risk of stroke/non-CNS SE, mortality, intracranial 
haemorrhage (ICH), and major bleeding.7 
 
In the phase III ROCKET AF study, rivaroxaban was tested in a population of patients with 
non-valvular AF (NVAF) with moderate-to-high stroke risk (mean CHADS2 score 3.5).
3 
Rivaroxaban was non-inferior to warfarin for preventing stroke/non-CNS SE, and was 
associated with a similar incidence of major bleeding events but significantly fewer fatal 
bleeding and ICH events versus warfarin.3 Based on these results, rivaroxaban was 
approved for stroke prevention in patients with NVAF at a dose of 20 mg once daily (od), with 
a 15 mg od dose recommended in patients with moderate-to-severe renal impairment 
(creatinine clearance [CrCl] 15–49 mL/min).8 
 
In clinical trials, adherence to the protocol, including measurement of renal function and 
adaptation of dose, is closely monitored and all patients should receive the recommended 
dose of the medication being tested. This contrasts with clinical practice, where non-
recommended doses may be prescribed.9 This analysis assesses clinical outcomes in 
patients enrolled in XANTUS receiving recommended or non-recommended rivaroxaban 
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doses according to the European label,8 and investigates potential patient characteristics that 
may have impacted the dose prescribed. 
Methods 
XANTUS was an international, prospective, observational study that investigated the use of 
rivaroxaban in routine clinical practice in Europe, Canada, and Israel; the study design was 
approved by the European Medicines Agency (EMA) and has been published previously.10 
Study population and screening 
Eligible patients aged ≥18 years with NVAF who had started rivaroxaban therapy to reduce 
the risk of stroke or non-CNS SE were identified. All patients provided written informed 
consent. Participating investigators were asked to screen all patients with AF receiving 
pharmacological treatment for stroke prevention, regardless of the treatment prescribed. 
Screening occurred before patients signed the informed consent forms; it was not 
permissible to collect any patient-related data from the remaining ineligible or non-consenting 
patients. To reduce selection bias, enrolment was consecutive and no eligible patient was to 
be omitted. The initial visit and initiation of rivaroxaban treatment were to take place within 
the enrolment period to rule out retrospective inclusion. 
Medication and follow-up 
Decisions about prescribing rivaroxaban were at the discretion of the treating physician; this 
included the dose and duration of therapy. In Europe, Israel, and Canada, the label-
recommended rivaroxaban dose for stroke prevention in patients with NVAF and normal or 
mild renal impairment (i.e. CrCl ≥50 mL/min) is 20 mg od.8 The rivaroxaban 15 mg od dose is 
the label-recommended dose for patients with moderate-to-severe renal impairment (CrCl 
15–49 mL/min) in Europe/Israel and for patients with moderate renal impairment (CrCl 30–49 
mL/min) in Canada. The Canadian label was updated after the completion of enrolment in 
XANTUS, and rivaroxaban 15 mg od can now also be used with caution in patients with 
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severe renal impairment (CrCl 15–<30 mL/min).8,11 After the initial screening visit, patients 
were followed up at approximately 3-month intervals. Patients were followed for 1 year, or 
until 30 days after permanent discontinuation (if <1 year), of rivaroxaban treatment. 
Study outcomes 
The main outcomes reported in this analysis are adjudicated treatment-emergent major 
bleeding (defined using the International Society on Thrombosis and Haemostasis [ISTH] 
definition12), all-cause death, stroke/non-CNS SE, thromboembolic events (the composite of 
stroke, non-CNS SE, transient ischaemic attack [TIA], and myocardial infarction [MI]), and 
the composite endpoint of adjudicated treatment-emergent major bleeding, stroke/non-CNS 
SE, and all-cause death. 
Study conduct 
A Central Adjudication Committee (CAC) assessed major events, specifically major bleeding, 
symptomatic thromboembolic events, and all-cause death. The CAC had access to all patient 
records. Both bleeding events and thromboembolic events were documented by the 
investigators as adverse events (AEs). In cases of potential stroke, non-CNS SE, TIA, or MI, 
either from an investigator assessment or a database search, central adjudication was 
performed. The CAC also adjudicated the type of stroke and occurrence of a haemorrhagic 
transformation of ischaemic stroke. Clinical cause of death was also centrally adjudicated. 
 
At each visit, explicit documentation was required regarding the potential occurrence of 
bleeding, stroke, non-CNS SE, TIA, MI, or any other AEs. Case Report Forms (CRFs) were 
designed to capture the data necessary for event adjudication. Additionally, the database 
was searched for concomitant medications, laboratory findings, or free text entries potentially 
indicating an undocumented AE of interest. Questionable findings from this search resulted 
in queries to the investigator and potentially, updates to the documentation in the CRF. 
Additionally, quality review and source data verification visits were performed at 61 (19.6%) 
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sites between Q4 2013 and Q3 2014, and documentation related to 581 patients (8.6%) was 
reviewed. 
Study governance 
The study complied with the Declaration of Helsinki, was approved by the appropriate Health 
Authorities, independent Ethics Committees and Independent Review Boards (as required) 
and was conducted in accordance with Good Pharmacoepidemiology Practice. An academic 
Steering Committee oversaw the design, execution, and conduct of the study, was 
responsible for manuscript development, had full access to all data and approved all versions 
of the manuscript. 
 
Informed consent for all patients included the permission for collection and analysis of study 
data. In compliance with good clinical practice (GCP) standards, data management and 
statistical analyses were overseen by the sponsor. The lead statistician oversaw 
programming and validation of the statistical analyses. 
Statistical analysis 
Statistical analyses were descriptive and exploratory and carried out in the safety population, 
defined as all patients who had taken at least one dose of rivaroxaban. Only treatment-
emergent events were considered, i.e. events that occurred from the day of the first 
rivaroxaban dose and up to 2 days after the last dose. 
 
In this post hoc, exploratory analysis, the baseline characteristics and outcomes of patients 
who received rivaroxaban using a dose in accordance with the European label8 were 
compared with those of patients who received a dose of rivaroxaban not in accordance with 
the European label (i.e. over-dosed with rivaroxaban 20 mg od when they had CrCl 15–49 
mL/min, under-dosed with 15 mg od when they had CrCl ≥50 mL/min, dosed with 15 mg od 
when they had CrCl <15 mL/min, or received a dose that was neither 20 mg od nor 15 mg 
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od). Both raw incidence proportions (events/number of patients treated) and incidence rates 
(events/100 patient-years) are presented, with corresponding 95% confidence intervals (CIs). 
A Kaplan–Meier plot was generated to show the time course up to the first event of interest in 
each group. Crude and baseline characteristic-adjusted hazard ratios (HRs) were generated 
to compare outcomes between the groups. The selection of baseline characteristics for the 
adjustment was based on medical judgement. 
 
A multivariable logistic regression with backwards selection procedure (P = 0.10) was 
performed to identify significant predictors of non-recommended dosing according to the 
European label. This P-value allowed for the identification of more potential predictors; a 
more restrictive P-value would have limited the number of predictors identified. In a further 
analysis, multivariable Cox regressions with backwards selection were carried out identifying 
predictors of the composite of major bleeding, stroke/non-CNS SE, and all-cause death 
separately for patients treated with label-recommended doses or other non-recommended 
doses. 
Results 
Patient population and dose received in relation to label recommendation 
Of the 6784 patients enrolled in the XANTUS study who received ≥1 dose of rivaroxaban: 
3608 (53.2%) received rivaroxaban in accordance with the European label and 856 (12.6%) 
received non-recommended doses; the remaining 2320 patients (34.2%) could not be 
classified, because of a lack of CrCl data (Figure 1). Of the patients who received non-
recommended doses, 232 (27.1%) were over-dosed (i.e. received rivaroxaban 20 mg od 
instead of 15 mg od), 583 (68.1%) were under-dosed (i.e. received rivaroxaban 15 mg od 
instead of 20 mg od), and 41 patients (4.8%) received other non-recommended rivaroxaban 
doses (6 patients had CrCl <15 mL/min and received rivaroxaban 15 mg od; 6 patients 
received rivaroxaban doses >20 mg od; 29 patients received rivaroxaban doses <15 mg od). 
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Of the patients with CrCl 15–<50 mL/min, those with CrCl closer to 15 mL/min were less 
likely to be over-dosed than those with CrCl closer to 50 mL/min; of the patients with CrCl 
15–<30 mL/min, 27% were over-dosed, and of the patients with CrCl 30–<50 mL/min, 36% 
were over-dosed. Most of the remaining patients in each group received the recommended 
dose of rivaroxaban 15 mg. 
Patient demographics and clinical characteristics 
The baseline demographics and clinical characteristics of patients stratified according to 
recommended or non-recommended dosing are shown in Table 1. Differences in baseline 
demographics between patients receiving recommended and non-recommended doses are 
shown in Table S1. The baseline characteristics of patients with unknown CrCl were very 
similar to those of patients receiving a recommended rivaroxaban dose. In patients receiving 
a non-recommended dose, the baseline characteristics of patients who were over-dosed with 
rivaroxaban 20 mg od were broadly similar to those of patients who were under-dosed with 
rivaroxaban 15 mg od; however, fewer males and more patients with prior MI were over-
dosed than under-dosed. The mean CHADS2 score was 1.9 in patients receiving a 
recommended rivaroxaban dose, 2.5 in patients who received a non-recommended dose, 
and 1.9 in patients with unknown CrCl at baseline. The mean HAS-BLED score was 2.0 in 
patients who received a recommended dose, 2.3 in patients receiving a non-recommended 
dose, and 1.9 in patients with unknown CrCl at baseline. Patients who received non-
recommended doses were older and more likely to have concomitant congestive heart 
failure, prior stroke/non-CNS SE/TIA, or diabetes; they were also more frequently started on 
rivaroxaban while in hospital (Table 1). 
Outcomes 
The overall number of treatment-emergent adjudicated major bleeding, stroke/non-CNS SE, 
and all-cause death events in patients who received recommended or non-recommended 
rivaroxaban doses increased progressively over time (Figure 2). The incidence rate 
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(events/100 patient-years) of treatment-emergent adjudicated major bleeding, stroke/non-
CNS SE, and all-cause death was 4.8 events/100 patient-years (95% CI 4.1–5.7) among 
patients receiving a recommended rivaroxaban dose and 7.5 events/100 patient-years (95% 
CI 5.7–9.8) among patients receiving a non-recommended dose (HR for non-recommended 
versus recommended dose = 1.55; 95% CI 1.15–2.10; P = 0.004) (Table 2). Patients who 
were over-dosed had 6.2 events/100 patient-years (95% CI 3.3–10.6) (HR = 1.28; 95% CI 
0.73–2.25; P = 0.393 versus patients who received the recommended dose), whereas under-
dosed patients had 7.6 events/100 patient-years (95% CI 5.4–10.4) (HR = 1.57; 95% CI 
1.10–2.22; P = 0.012 versus patients who received the recommended dose) (Table 3 and 
Figure 3). The incidence rate in patients whose CrCl was unknown was 2.4 events/100 
patient-years (95% CI 1.8–3.2) (HR = 0.50; 95% CI 0.36–0.68; P <0.001 versus patients who 
received the recommended dose). After adjustment for baseline characteristics, differences 
in rates of treatment-emergent adjudicated major bleeding, stroke/non-CNS SE, and all-
cause death between patients receiving recommended or non-recommended doses were no 
longer statistically significant (HR non-recommended versus recommended = 1.06; 95% CI 
0.77–1.45; P = 0.719) (Table 2 and Figure 3). Multivariable Cox regression analysis identified 
liver disease (HR = 2.55; 95% CI 1.28–5.06, P = 0.007) and congestive heart failure 
(HR = 2.14; 95% CI 1.51–3.02, P <0.001) as strong predictors of treatment-emergent 
adjudicated major bleeding, stroke/non-CNS SE, and all-cause death in patients who 
received recommended doses (Table S2A). In patients who received a non-recommended 
dose of rivaroxaban, congestive heart failure (HR = 1.97; 95% CI 1.16–3.36, P = 0.012) and 
hospitalisation at baseline (HR = 1.87; 95% CI 1.09–3.19, P = 0.022) were identified as 
predictors of major bleeding, stroke/non-CNS SE, and all-cause death (Table S2B). 
 
The incidence rate of adjudicated treatment-emergent major bleeding events was 2.6 
events/100 patient-years (95% CI 2.1–3.3) for patients who received a recommended dose, 
3.7 events/100 patient-years (95% CI 2.5–5.3) for patients who received a non-
recommended dose, and 0.7 events/100 patient years (95% CI 0.4–1.1) for patients whose 
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CrCl was unknown. Corresponding rates for stroke/non-CNS SE were 0.9 events/100 
patient-years (95% CI 0.6–1.3) for patients receiving a recommended dose, 1.4 events/100 
patient-years (95% CI 0.7–2.6) for patients receiving a non-recommended dose, and 0.5 
events/100 patient-years (95% CI 0.3–0.9) for patients whose CrCl was unknown. 
 
Incidence rates of all-cause death were 1.9 events/100 patient-years (95% CI 1.5–2.4) for 
patients receiving a recommended dose, 3.5 events/100 patient-years (95% CI 2.3–5.1) for 
patients receiving a non-recommended dose, and 1.4 events/100 patient-years (95% CI 0.9–
2.0) for patients whose CrCl was unknown. The incidence rates of major bleeding, 
stroke/non-CNS SE, and all-cause death, stratified according to CrCl and label adherence 
are presented in Figure 4, but these results should be interpreted with caution because of the 
small sample size resulting in wide CIs. 
 
Multivariable analysis identified the following as independent predictors of receiving a non-
recommended dose of rivaroxaban: older age (odds ratio [OR] = 1.06 per 1-year increase; 
95% CI 1.04–1.07); lower body weight (OR = 0.99 per 1-kg increase; 95% CI 0.99–1.00); 
presence of anaemia or reduced haemoglobin levels (OR = 1.78; 95% CI 1.25–2.53); CrCl 
≥50 mL/min plus CrCl missing as opposed to CrCl <50 mL/min (OR = 0.54; 95% CI 0.44–
0.66); presence of congestive heart failure (OR = 1.32; 95% CI 1.09–1.60), diabetes mellitus 
(OR = 1.33; 95% CI 1.09–1.61), or vascular disease (OR = 1.29; 95% CI 1.08–1.54); being 
treated by a general practitioner as opposed to a cardiologist/neurologist (OR = 0.62; 95% CI 
0.46–0.83) or other specialist (OR = 0.49; 95% CI 0.31–0.78); and paroxysmal AF 
(OR = 0.75; 95% CI 0.60–0.93) or permanent AF (OR = 0.77; 95% CI 0.61–0.97) as opposed 
to first diagnosed AF (Table 4). 
Discussion 
This post hoc analysis of the XANTUS real-world study provided an opportunity to estimate 
the incidence rates of major bleeding, stroke/non-CNS SE, and all-cause death in patients 
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treated with rivaroxaban in accordance with European label recommendations versus those 
treated with a non-recommended dose (i.e. over-dosed with rivaroxaban 20 mg od instead of 
rivaroxaban 15 mg od in patients with CrCl 15–49 mL/min, or under-dosed with rivaroxaban 
15 mg od instead of rivaroxaban 20 mg od in patients with CrCl ≥50 mL/min) in routine 
clinical practice. The incidence rate of the composite of treatment-emergent adjudicated 
major bleeding, stroke/non-CNS SE or all-cause death was significantly higher in patients 
who received a non-recommended dose versus those who received a recommended dose. 
This increase appeared to be driven by a higher rate of all-cause death; however, these 
differences were non-significant after adjustment for baseline characteristics. This suggested 
that where a non-recommended rivaroxaban dose was prescribed, the dosage was not 
selected based solely on CrCl (as recommended in the label), but was also based on other 
patient characteristics associated with stroke and bleeding risks such as age, lower body 
weight, congestive heart failure, diabetes mellitus, anaemia, or reduced haemoglobin, type of 
AF, and CrCl <50 mL/min as opposed to CrCl ≥50 mL/min or CrCl missing.  
 
General practitioners were more likely to prescribe a non-recommended dose than 
cardiologists/neurologists or other specialists; the non-recommended doses prescribed in 
XANTUS may reflect more cautious prescribing in routine clinical practice in patients deemed 
to be frail and with a high bleeding risk, and in those with higher baseline CHADS2 scores. It 
is well known that bleeding and stroke risk factors overlap.2 The interpretation of the 
comparisons between patients receiving recommended or non-recommended doses is 
complicated by the inclusion of over-dosed and under-dosed patients in a single group 
(Table 2). It would be expected that the risk of thromboembolic events would increase with 
under-dosing (as was shown for ischaemic stroke in the edoxaban 30 mg od arm of the 
ENGAGE AF-TIMI 48 trial)6 and the risk of bleeding would increase with over-dosing. 
However, there is no evidence that lower dosing is associated with better outcomes, and in 
fact it may increase thromboembolic risk, with this analysis showing that there was a trend 
towards a higher risk of major bleeding, stroke/non-CNS SE, and all-cause death in under-
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dosed patients. It is unclear if label-recommended rivaroxaban 20 mg od would have resulted 
in lower incidence rates in this group; however, because these rates may be attributable to 
the characteristics of these patients rather than to the dose used, this question would be best 
addressed in randomised studies. In addition, patients who received a higher than 
recommended rivaroxaban dose had lower rates of major bleeding than those patients who 
were under-dosed, further linking outcomes in under-dosed patients to baseline 
characteristics rather than to the dose received. It should be noted that none of these 
differences between over-dosed and under-dosed patients were significant; this sub-analysis 
was not powered to detect differences between these groups and these trends should be 
interpreted with caution. The baseline characteristics identified in this study show which 
factors may influence dosing decisions in clinical practice, but the evidence is not sufficient to 
support a label recommendation for dose adjustment according to these characteristics. In 
the pivotal phase III ROCKET AF study, dosing was based on renal function only, and the 
rivaroxaban label recommends dosing accordingly.3,8 
 
All-cause death was the only component of the composite outcome that was significantly 
different between patients receiving non-recommended versus recommended rivaroxaban 
doses groups, before, but not after, adjusting for baseline characteristics (Table 2). This 
suggests that patients receiving non-recommended doses could have an increased risk of 
death due to baseline differences in co-morbidities. Causes of death were not analysed 
according to dose in this study, but included cardiovascular death (41.5%), death due to 
bleeding (10.2%), cancer (19.5%) and infectious disease (8.5%) in the overall XANTUS 
population, with the remainder of patients having unexplained (7.6%) or other (13.6%) 
causes of death.13 
 
In the ORBIT-AF II real-world registry, there were similar observations. Of 5738 patients 
included and treated with a NOAC, 541 (9.4%) were under-dosed, 197 (3.4%) were over-
dosed, and 5000 (87%) were treated in accordance with the respective label. Patients 
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receiving non-recommended doses were older, more likely to be female, less likely to be 
treated by an electrophysiologist, and had higher CHA2DS2-VASc scores and ORBIT 
bleeding risk scores. After adjustment, over-dosing with NOACs was associated with an 
increased all-cause death and under-dosed patients were more likely to be hospitalised for 
cardiovascular endpoints.14 In another analysis from the ORBIT-AF II registry, patients who 
received non-recommended, reduced-dose NOACs were at an increased risk of 
thromboembolic events and death. This association was no longer significant after 
adjustment for differences in patient characteristics.15 
Limitations 
XANTUS was a single-arm study and, as with any open-label study, the study design can 
introduce bias related to treatment knowledge, for example self-selection bias when patients 
decide whether to provide consent and selection bias due to investigators enrolling patients 
with intact cognitive function. The main limitation of this analysis was that it is unknown if 
patients with missing CrCl levels were dosed per label recommendation or not; such a lack of 
information is a common drawback of real-world studies. Although CrCl might not have been 
measured in some cases, it is also possible that some CrCl measurements were simply not 
documented. The baseline characteristics of these patients were very similar to those of the 
patients treated in accordance with the label (although a much lower proportion were 
hospitalised at baseline – 4.7% versus 24.1%, suggesting that these patients may have been 
healthier generally and probably had normal renal function). Furthermore, the incidence rates 
of treatment-emergent adjudicated composite and individual endpoints were much lower in 
these patients with missing CrCl levels than in patients receiving recommended or non-
recommended dosing. In patients receiving higher than recommended versus lower than 
recommended doses, the number of events was too low to allow a full comparison of each 
outcome. Further limitations were that, due to the non-interventional design, treatment 
adherence and compliance were not measured and persistence was not compared between 
patient groups; therefore, possible differences in the duration of rivaroxaban treatment 
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between patient groups were not accounted for. It was not possible to ask prescribing 
physicians to record the reason why they selected the prescribed dose because this might 
have affected the choice of dose; this also made it possible to determine what proportion of 
patients did not have CrCl measurements in a real-world setting. The reasons for selecting 
the prescribed dose would have provided insight as to whether the choice of a non-
recommended dose was due to prescriber error or based on the baseline characteristics of 
the patients. Although a large number of baseline characteristics were recorded, it is possible 
that other clinical characteristics that were not recorded systematically, such as chronic lung 
disease, concomitant therapy (e.g. steroid use), history of bleeding, recent surgery, and 
thrombocytopenia, could have influenced prescription decisions; these characteristics could 
not be adjusted for in the analysis. The lack of data on surgery also means that the higher 
risk of bleeding in patients with post-operative AF could not be considered when assigning 
patients to groups.  
Conclusion 
Overall, patients in the real-world XANTUS study who were treated with a non-recommended 
rivaroxaban dose (both over- and under-dosed) appeared to be at a higher risk of major 
bleeding, stroke/non-CNS SE, and all-cause death than patients receiving a recommended 
dose. After adjusting for the baseline characteristics of patients receiving a non-
recommended dose, these differences were no longer significant. The higher event rates 
among patients receiving a non-recommended dose are probably related to the underlying 
disease rather than the dose itself. Patient characteristics, other than CrCl levels, that may 
affect dosing decisions were identified, which demonstrates that physicians may not always 
follow label recommendations. In the absence of robust evidence on the effects of patient 
characteristics on outcomes, however, dosing should continue to be according to the label 
and physician education to emphasise this should be improved.  
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Figure legends 
Figure 1 Patient disposition and rivaroxaban dosing during the XANTUS study. 
 
Figure 2 Time to first treatment-emergent adjudicated major bleeding, stroke/non-CNS SE, 
or all-cause death according to recommended or non-recommended rivaroxaban dose. 
 
Figure 3 Composite of treatment-emergent adjudicated outcomes (major bleeding, 
stroke/non-CNS SE, or all-cause death). 
aAdjusted for age (continuous), sex, first available weight (continuous), hypertension, 
diabetes mellitus, prior stroke/TIA/non-CNS systemic embolism, congestive heart failure, 
hospitalised at baseline, patient treated by (general practitioner, cardiologist/neurologist, or 
other), anaemia, or reduced haemoglobin. 
 
Figure 4 Incidence rates of adjudicated major bleeding, stroke/non-CNS SE, and all-cause 
death stratified by CrCl and recommended or non-recommended rivaroxaban dosing. 
aNumber of events and number of patients with events: 0. 
b95% CI. 
Table 1 Demographics of XANTUS patients stratified by dose received according to the European label 
  
Recommended 
dosing 
(n = 3608) 
Recommended 
dosing with 
rivaroxaban 
20 mg od 
(n = 3211) 
Non-
recommended 
dosing 
(n = 856) 
Unknown
a
 
(n = 2320) 
Over-dosed 
with 
rivaroxaban 
20 mg od 
(n = 232) 
Under-
dosed with 
rivaroxaban 
15 mg od 
(n = 583) 
Age years, mean 
(SD) 
70.5 (9.92) 69.3 (9.58) 76.6 (8.71) 71.2 (9.86) 76.3 (7.98) 76.7 (8.87) 
<65 years, % 24 26.7 9.9 22.8 7.8 10.6 
    43.8 47 28.5 41.2 32.3 27.1 
>75 years, % 32.2 26.3 61.6 36 59.9 62.3 
Male, % 60.7 62.6 51.1 59.9 40.1 55.2 
BMI, kg/m
2
, mean 
(SD) 
28.4 (5.0) 28.6 (5.0) 27.4 (4.8) 28.6 (5.0) 26.8 (5.4) 27.6 (4.6) 
CrCl, mL/min, %             
<15 0 – 2.3 – 6 0 
≥15–<30 1.5 – 2.5 – 8.6 0 
≥30–<50 9.5 – 23.6 – 85.3 0 
≥50–≤80 52.2 58.6 55.1 – 0 79.1 
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>80 36.8 41.4 14.8 0.1%
b
 0 2 0.9 
Missing 0 – 1.6 99.90% 0 0 
AF type, first 
diagnosed, % 
18.5 18.3 23.1 16.8 19.8 23.5 
Paroxysmal 42.9 43.6 36 38.8 33.2 37 
Persistent 13.7 13.7 13 13.6 15.5 12.3 
Permanent 24.8 24.1 27.6 30.4 31.5 26.8 
Existing co-
morbidities, % 
            
Hypertension 75.2 74.2 79.1 72.2 79.3 79.8 
Diabetes mellitus 19.6 18.8 23.9 18.2 22.8 24.2 
Prior stroke/SE/TIA 18.5 17.7 24.2 17.9 24.1 24.2 
Prior MI 10 8.9 11.8 9.8 15.1 10.6 
CHF 18.6 16.8 26.8 15.8 29.7 26.8 
Hospitalisation at 
baseline, % 
24.1 23.4 29.2 4.7 25.4 29.5 
CHADS2 score, 
mean (SD) 
1.9 (1.3) 1.8 (1.2) 2.5 (1.2) 1.9 (1.3) 2.5 (1.3) 2.5 (1.2) 
CHA2DS2-VASc 
score, mean (SD) 
3.3 (1.7) 3.1 (1.6) 4.2 (1.6) 3.3 (1.7) 4.4 (1.6) 4.1 (1.5) 
HAS-BLED score, 
mean (SD) 
2.0 (1.0) 1.9 (1.0) 2.3 (1.1) 1.9 (1.0) 2.4 (1.0) 2.3 (1.1) 
Concomitant 
antiplatelet/NSAID 
use, % 
18.9 18.9 19.3 16.9 16.4 19.4 
Prior acetylsalicylic 
acid therapy, % 
19 18.7 16.7 17.1 11.6 19 
Prior DAPT, % 1 1 1.4 0.9 0.4 1.9 
 
AF, atrial fibrillation; BMI, body mass index; CHF, congestive heart failure; CrCl, creatinine 
clearance; DAPT, dual antiplatelet therapy; MI, myocardial infarction; NSAID, non-steroidal 
anti-inflammatory drug; od, once daily; SD, standard deviation; SE, systemic embolism; TIA, 
transient ischaemic attack. 
aCrCl missing.b2 patients erroneously had a missing dose recorded and were included in the 
CrCl unknown group (despite CrCl measurements being available). 
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Table 2 Adjudicated treatment-emergent outcomes according to recommended or non-
recommended rivaroxaban dose in patients enrolled in XANTUS  
 
  
Recommended dose 
(n = 3608) 
Non-recommended 
dose (n = 856) 
Unadjusted HR 
(95% CI) 
P-
value 
Adjusted HR
a
 
(95% CI) 
P-value Inciden
ce 
proport
ion, n 
(%) 
Incidence 
rate, 
events/100 
patient-years 
(95% CI) 
Inciden
ce 
proport
ion,n 
(%) 
Incidence 
rate, 
events/100 
patient-
years (95% 
CI) 
Non-
recommended 
dose vs. 
recommended 
dose 
Non-
recommended 
dose vs. 
recommended 
dose 
Major bleeding, 
stroke/non-CNS 
SE, or all-cause 
death 
157 
(4.4) 
4.8 (4.1–5.7) 57 (6.7) 7.5 (5.7–9.8) 1.55 (1.15–2.10) 0.004 1.06 (0.77–1.45) 0.719 
All-cause mortality 62 (1.7) 1.9 (1.5–2.4) 27 (3.2) 3.5 (2.3–5.1) 1.86 (1.19–2.93) 0.007 1.24 (0.77–1.98) 0.378 
Thromboembolic 
events (stroke, TIA, 
non-CNS SE, or 
MI) 
62 (1.7) 1.9 (1.5–2.4) 21 (2.5) 2.8 (1.7–4.2) 1.45 (0.89–2.39) 0.138 1.19 (0.71–1.99) 0.499 
Stroke/non-
CNS SE 
29 (0.8) 0.9 (0.6–1.3) 11 (1.3) 1.4 (0.7–2.6) 1.63 (0.81–3.27) 0.167 1.27 (0.62–2.61) 0.51 
Major bleeding 
events 
86 (2.4) 2.6 (2.1–3.3) 28 (3.3) 3.7 (2.5–5.3) 1.39 (0.91–2.13) 0.132 0.99 (0.63–1.54) 0.958 
Fatal bleeding 7 (0.2) 0.2 (0.1–0.4) 3 (0.4) 0.4 (0.1–1.1) 1.84 (0.48–7.11) 0.377 2.06 (0.48–8.75) 0.328 
Critical organ 
bleeding 
26 (0.7) 0.8 (0.5–1.2) 10 (1.2) 1.3 (0.6–2.4) 1.64 (0.79–3.41) 0.182 1.37 (0.64–2.94) 0.417 
ICH 15 (0.4) 0.5 (0.3–0.8) 7 (0.8) 0.9 (0.4–1.9) 2.00 (0.81–4.9) 0.131 1.76 (0.69–4.50) 0.24 
 
aAdjusted for the following additional covariates: age (continuous); sex; first available weight 
(continuous); hypertension; diabetes mellitus; prior stroke/TIA/non-CNS SE; congestive heart 
failure; hospitalised at baseline; patient treated by (general practitioner, 
cardiologist/neurologist, other); and anaemia or reduced haemoglobin. 
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Table 3 Adjudicated treatment-emergent outcomes in patients enrolled in XANTUS 
according to non-recommended dose 
  
Over-dosed with rivaroxaban 
20 mg od (n = 232) 
Under-dosed with 
rivaroxaban 15 mg od 
(n = 583) 
HR (95% CI) 
over-dosed vs. 
under-dosed 
P-value 
Incidence 
proportion n 
(%) 
Incidence rate, 
events/100 
patient-years 
(95% CI) 
Incidence 
proportion 
n (%) 
Incidence 
rate, 
events/100 
patient-years 
(95% CI) 
Major bleeding, stroke/non-
CNS SE, or all-cause death 
13 (5.6) 6.2 (3.3–10.6) 39 (6.7) 7.6 (5.4–10.4) 0.82 (0.44–1.53) 0.527 
All-cause mortality 8 (3.4) 3.8 (1.6–7.5) 16 (2.7) 3.1 (1.8–5.0) 1.23 (0.53–2.88) 0.629 
Thromboembolic events 
(stroke, TIA, non-CNS SE, 
or MI) 
6 (2.6) 2.9 (1.1–6.3) 14 (2.4) 2.7 (1.5–4.6) 1.05 (0.4–2.74) 0.914 
Stroke/non-CNS SE 2 (0.9) 1.0 (0.1–3.4) 9 (1.5) 1.7 (0.8–3.3) 0.54 (0.12–2.51) 0.435 
Major bleeding events 6 (2.6) 2.9 (1.0–6.2) 20 (3.4) 3.9 (2.4–6.0) 0.74 (0.3–1.83) 0.511 
Fatal bleeding 1 (0.4) 0.5 (0.0–2.6) 2 (0.3) 0.4 (0.0–1.4) 
1.22 (0.11–
13.46) 
0.871 
Critical organ bleeding 2 (0.9) 1.0 (0.1–3.4) 8 (1.4) 1.5 (0.7–3.0) 0.62 (0.13–2.9) 0.539 
ICH 2 (0.9) 1.0 (0.1–3.4) 5 (0.9) 1.0 (0.3–2.2) 0.98 (0.19–5.07) 0.985 
 
Table 4 Multivariate logistic regression analysisa of predictors of use of a non-recommended 
dose of rivaroxaban 
Predictor 
Odds ratio (95% 
CI) 
P-value 
Age: per 1-year increase 1.06 (1.04–1.07) < 0.001 
First available CrCl: ≥50 mL/min or missing CrCl 
vs. <50 mL/min 
0.54 (0.44–0.66) < 0.001 
Anaemia or reduced haemoglobin: yes vs. no 1.78 (1.25–2.53) 0.001 
Patient treated by: overall   0.002 
Cardiologist/neurologist vs. GP 0.62 (0.46–0.83) 0.001 
Other specialist vs. GP 0.49 (0.31–0.78) 0.003 
First available weight: per 1-kg increase 0.99 (0.99–1.00) 0.004 
Vascular disease: yes vs. no 1.29 (1.08–1.54) 0.004 
Diabetes mellitus: yes vs. no 1.33 (1.09–1.61) 0.005 
Congestive heart failure: yes vs. no 1.32 (1.09–1.60) 0.005 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvy041/5181122 by guest on 29 N
ovem
ber 2018
 22 
Atrial fibrillation type: overall   0.055 
Paroxysmal vs. first diagnosed 0.75 (0.60–0.93) 0.009 
Persistent vs. first diagnosed 0.82 (0.62–1.09) 0.176 
Permanent vs. first diagnosed 0.77 (0.61–0.97) 0.026 
 
CI, confidence interval; CNS, central nervous system; CrCl, creatinine clearance; GP, 
general practitioner; SE, systemic embolism; TIA, transient ischaemic attack. 
aA logistic regression model using a backward selection procedure was used to exclude a 
variable with the highest P-value at a time. The significance level for keeping variables in the 
model was P = 0.10. Potential predictors included in the model that were not identified as 
predictors of non-recommended dosing were: sex; hypertension; prior stroke/TIA/non-CNS 
SE; hospitalised at baseline; liver disease. 
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